Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Kodiak's Zenkuda drug met key trial targets for diabetic retinopathy, boosting investor confidence.
Kodiak Sciences shares surged after its drug Zenkuda met primary endpoints in a late-stage diabetic retinopathy trial.
The treatment showed significant improvement in disease severity and reduced sight-threatening complications, with a strong safety profile.
The company plans to accelerate regulatory submissions, boosting investor confidence.
9 Articles
El medicamento Zenkuda de Kodiak cumplió con objetivos clave de ensayo para la retinopatía diabética, aumentando la confianza de los inversores.